Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Edition
European
US
Diabetes
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
GLP-1s May be Effective Treatments for Mental Illness in Diabetes
April 2026
Semaglutide is associated with a lower risk of worsening anxiety, depression, and substance use disorder in patients with co-occurring mental illness and diabetes.
Read more
4 Apr 2026
GLP-1s May be Effective Treatments for Mental Illness in Diabetes
Semaglutide is associated with a lower risk of worsening anxiety, depression, and substance use disorder in patients with co-occurring mental illness and diabetes.
2 Apr 2026
More Than One Million People to be Offered Semaglutide on NHS
Semaglutide is set to be offered to more than one million people with cardiovascular disease on the NHS in coming months.
28 Mar 2026
Metabolically Healthy Child Obesity Still Raises Cardiometabolic Risk
Children with metabolically healthy obesity still face increased cardiometabolic risks by adulthood, highlighting the need for early intervention.
27 Mar 2026
Metformin: Hidden Brain Pathway to Lower Blood Sugar Revealed
Scientists have discovered a previously unknown neural pathway behind the antidiabetic effects of metformin, a standard first-line treatment for Type 2 diabetes.
26 Mar 2026
Stopping GLP-1s Increases Risk of Cardiovascular Disease
Discontinuation of, or interruptions to, GLP-1 treatment may increase the risk of major adverse cardiovascular events in adults with Type 2 diabetes.
24 Mar 2026
Type 1 Diabetes Tied to Threefold Increase in Dementia Risk
Adults above 50 with Type 1 diabetes are nearly three times as likely to develop incident dementia as those without. Read more.
21 Mar 2026
Metformin May Reduce Risk of Age-Related Macular Degeneration
Metformin reduces the incidence of intermediate age-related macular degeneration by nearly 40% in people with Type 2 diabetes, a 2026 study has found.
19 Mar 2026
Half of Patients with Type 2 Diabetes Have Fatty Pancreas Disease
Around 50% of patients with Type 2 diabetes have fatty pancreas disease, a substantial yet arguably overlooked metabolic burden.
Loading posts...
1
2
3
…
46
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View